 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at Massachusetts General Hospital evaluating the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19. Mallinckrodts support to Massachusetts General Hospital includes providing funding as well as INOmax nitric oxide gas, for inhalation, to facilitate the study. 